Zealand drug candidates featured at ADA Science Sessions

Zealand announced that data on its iGlarLixi drug candidates are being presented recently during the American Diabetes Association’s (ADA) Scientific Sessions in New Orleans.

During the session, the company will detail its pre-clinical activities that include a peptide drug candidate that is currently in pre-clinical development and testing.

The drug iGlarLixi is a fixed-ratio combination of insulin glargine at 100 units per milliliter and lixisenatide.

One presentation took place on Sunday, June 12, and it was presented by Dr. Vanita Aroda of the Medstar Health Research Institute. This session covered the efficacy and safety trial of iGlarLixi over a period of 30  weeks and consisted of patients that had not seen adequate control over blood sugar levels on insulin or antidiabetic medications by themselves. In this study it was found that baseline glycated hemoglobin, or HbA1c, fell by a significant amount after the 30 week period.

Researchers also note that the candidate treatment was well tolerated and had a positive impact on weight loss in patients during the study.

Jolanta Skarbaliene of Zealand presented information on the effects of a novel drug candidate, amylin analogue ZP4982, in animal models. The abstract states that the candidate drug was found to facilitate glycemic control by inhibiting food intake. It also resulted in increased insulin levels.